Condition
Symptomatic Neurogenic Orthostatic Hypotension (NOH)
Total Trials
3
Recruiting
0
Active
0
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
67%
2 trials in Phase 3/4
Results Transparency
100%
2 of 2 completed with results
Key Signals
2 with results100% success
Data Visualizations
Phase Distribution
3Total
P 2 (1)
P 3 (2)
Trial Status
Completed2
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT00633880Phase 3CompletedPrimary
Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)
NCT00782340Phase 3CompletedPrimary
A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa
NCT00758849Phase 2UnknownPrimary
Fipamezole in Neurogenic Orthostatic Hypotension
Showing all 3 trials